PMID- 35422192
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20221222
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 63
IP  - 9
DP  - 2022 Sep
TI  - Real-world healthcare resource utilization and costs associated with 
      tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large 
      B-cell lymphoma: an analysis of hospital data in the United States.
PG  - 2052-2062
LID - 10.1080/10428194.2022.2060503 [doi]
AB  - This study compared the real-world healthcare resource utilization (HRU), costs, 
      adverse events (AEs), and AE treatments associated with the chimeric antigen 
      receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene 
      ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r 
      DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the 
      Premier Healthcare Database (2017-2020). Non-CAR-T costs, HRU, and AE rates 
      during the infusion and follow-up periods were compared between the tisa-cel and 
      axi-cel cohorts. Of 119 patients, 33 received tisa-cel (86% as inpatient 
      infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with 
      significantly shorter mean inpatient length of stay than axi-cel during infusion 
      (11.3 vs. 18.3 days) and follow-up ([monthly] 3.9 vs. 6.9 days). Non-CAR-T costs 
      were significantly lower for tisa-cel compared with axi-cel during infusion 
      ($27594.8 vs. $51378.3) and follow-up ([monthly] $28777.3 vs. $46575.7; both 
      p< .05). Rates of AEs and AE treatments were similar.
FAU - Maziarz, Richard T
AU  - Maziarz RT
AD  - Center for Hematologic Malignancies, Oregon Health and Science University, 
      Portland, OR, USA.
AD  - Knight Cancer Institute, Oregon Health &amp; Science University, Portland, OR, 
      USA.
FAU - Yang, Hongbo
AU  - Yang H
AD  - Analysis Group, Inc., Boston, MA, USA.
FAU - Liu, Qing
AU  - Liu Q
AD  - Analysis Group, Inc., Boston, MA, USA.
FAU - Wang, Travis
AU  - Wang T
AD  - Analysis Group, Inc., Boston, MA, USA.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Analysis Group, Inc., Boston, MA, USA.
FAU - Lim, Stephen
AU  - Lim S
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Lee, Soyon
AU  - Lee S
AUID- ORCID: 0000-0002-2059-717X
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Dalal, Anand
AU  - Dalal A
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Bollu, Vamsi
AU  - Bollu V
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20220414
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, CD19)
RN  - 0 (Biological Products)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Receptors, Chimeric Antigen)
RN  - Q6C9WHR03O (tisagenlecleucel)
RN  - U2I8T43Y7R (axicabtagene ciloleucel)
SB  - IM
CIN - Leuk Lymphoma. 2022 Sep;63(9):2019-2020. PMID: 35821624
MH  - Adult
MH  - Antigens, CD19
MH  - *Biological Products/therapeutic use
MH  - Delivery of Health Care
MH  - Hospitals
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - Receptors, Antigen, T-Cell
MH  - *Receptors, Chimeric Antigen
MH  - United States/epidemiology
OTO - NOTNLM
OT  - Adverse events
OT  - axicabtagene ciloleucel
OT  - diffuse large B-cell lymphoma
OT  - healthcare costs
OT  - healthcare resource utilization
OT  - tisagenlecleucel
EDAT- 2022/04/16 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/04/15 05:19
PHST- 2022/04/16 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/04/15 05:19 [entrez]
AID - 10.1080/10428194.2022.2060503 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2022 Sep;63(9):2052-2062. doi: 10.1080/10428194.2022.2060503. Epub 
      2022 Apr 14.